Fact CheckerSign in

NCT07266675Recruiting

Post-Acute Phase of Cardiogenic Shock

Post-Acute Phase of Cardiogenic Shock (PACS) Registry

Source: ClinicalTrials.gov · Last updated 5 Dec 2025

Brief summary (registry, in English)

Epidemiology studies showed that the burden of cardiogenic shock (CS) persistently high, with increasing annual medical expenses and steady prevalence. In-hospital and one-year mortality reduce annually. Hence, there are increasing number of patients who survive to hospital discharge but they will face further challenges in the subacute stage after hospital discharge. However, there are still insufficient studies focusing on this issue. Establishment of a healthcare neatwork to help hospital survivors of CS return society safely is critical.

Status (registry)
Recruiting
Study type
Observational
Enrollment
350 (estimated)
First submitted
24 Nov 2025
Start date
19 Jul 2024
Primary completion date
30 Jun 2027
Lead sponsor
Mackay Memorial Hospital
NCT number
NCT07266675

What you commit to

  • Study type: Observational
  • Planned participants: 350
  • From 19 Jul 2024 to the primary completion date, 30 Jun 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Age \< 18 years。

Other

  • Patient or family refuse follow-up.
  • Patient died within hospital stay.

Who the study is looking for

  • Hospital survivors of cardiogenic shock

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
MacKay Memorial Hospital
Coordinator of this site? Confirm its status
TaipeiTaiwanRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.